|
|
MOLT-4
|
|
|
J Minowada
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
|
See Propagation
|
|
|
suspension
|
|
|
Homo sapiens
|
|
|
lymphoblast
|
|
|
Disease: acute lymphoblastic leukemia
Cell Type: T lymphoblast;
|
|
|
high levels of terminal deoxynucleotidyl transferase (TdT) are produced
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
transfection host
|
|
|
Yes
|
|
|
CD1 (49%), CD2 (35%), CD3 A (26%) B (33%) C (34%), CD4 (55%), CD5 (72%), CD6 (22%), CD7 (77%)
|
|
|
Amelogenin: XY
CSF1PO: 11, 12, 13
D13S317: 12, 13
D16S539: 11, 14
D5S818: 12
D7S820: 8, 10, 11
THO1: 6, 8
TPOX: 8
vWA: 17, 18
|
|
|
This is a human cell line with the hypertetraploid chromosome number. The modal chromosome number was 95 occurring in 24% of cells. The rate of cells with higher ploidies was 0.8%. The 6q- and t(7;7) were paired and also common to all cells. The i(17q) was single and occurred only in some cells. Most normal chromosomes had four copies per cell except for the paired N7, X and Y, and two to three copies for N17.
|
|
|
19 years
|
|
|
male
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
|
|
|
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start new cultures at 4 X 10(5) cells/ml and subculture before the cell density reaches 2 X 10(6) cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
|
|
|
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
derived from same individual:ATCC CRL-1552
|
|
|
22524: Minowada J, et al. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J. Natl. Cancer Inst. 49: 891-895, 1972. PubMed: 4567231
22550: Ohsugi Y, et al. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X- irradiated nude mice. J. Natl. Cancer Inst. 65: 715-718, 1980. PubMed: 6932523
22735: Mertelsmann R, et al. T-cell growth factor (interleukin 2) and terminal transferase activity in human leukemias and lymphoblastic cell lines. Blut 43: 99-103, 1981. PubMed: 6942897
23322: Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228
23337: Sandstrom PA, Buttke TM. Autocrine production of extracellular catalase prevents apoptosis of the human CEM T-cell line in serum-free medium. Proc. Natl. Acad. Sci. USA 90: 4708-4712, 1993. PubMed: 8506323
|
